Stada Group
Christos Gallis serves as the Executive Vice President at STADA Group since February 2019, where responsibilities include overseeing operations in Eastern Europe and Eurasia as a member of the Global Executive Committee. Previously, Christos held various leadership positions at Sandoz from June 2009 to January 2019, managing markets in Central, Eastern, and Southern Europe, the Baltics, Ukraine, and Israel. Prior experience includes roles at Johnson & Johnson, culminating in the position of Managing Director for the Czech and Slovak Republics. Christos began career as Sales Director at Johnson & Johnson Hellas. Academic credentials include an MBA in Marketing and Strategy from The University of Chicago Booth School of Business, courses on Public Policy at Harvard University, and a Bachelor's degree in Economics from National & Kapodistrian University of Athens.
This person is not in any offices
Stada Group
14 followers
Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products. The Branded Products segment focuses on multisource products accessible without active ingredient research, notably anti-enzymatic food intolerance drugs that are marketed by the subsidiary SCIOTEC Diagnostics Technologies. The Company's generic drugs are marketed by the Group subsidiary, STADApharm GmbH. Non-core activities of the Company encompass Commercial Business segment, which includes activities with primarily trading character such as wholesaling activities. The Company operates STADA Pharmaceuticals Australia Pty Ltd and STADA IT SOLUTIONS DOO as subsidiaries.